STEMTECH CORPORATION - STEK STOCK NEWS

Stemtech (OTCQB:STEK) is positioning itself as a leader in the wellness and anti-aging sectors with its natural, plant-based nutritional stemceuticals™. The company operates in a rapidly expanding market, with the Global Wellness Economy reaching $6.3 trillion and projected to hit $9 trillion by 2028, currently four times larger than the global pharmaceutical industry.

The company's product portfolio includes stemrelease3™, StemFlo™ Advanced, MigraStem®, OraStem® Toothpaste, and recent launches like Cellect One® Shield and Cellect One® Rapid Renew Stem Cell Peptide Night Cream. Stemtech plans to enter the pet wellness market with StemPets™ in April 2025, targeting the $303 billion global pet wellness market.

Stemtech (OTCQB:STEK) announced a proposed Reverse Takeover (RTO) of Eevia Health Plc, following its planned merger with Seacret Direct (VIÁGO). Under the RTO, Eevia will acquire Stemtech's assets and liabilities, with Stemtech owning approximately 85% of Eevia post-transaction.

The strategic combination aims to create a vertically integrated health and wellness entity, utilizing Eevia's Finnish production facility for manufacturing Stemtech and VIÁGO's products. The merged entity will combine Stemtech's stem cell nutrition technology with VIÁGO's lifestyle offerings, serving over 250,000 affiliated members across 40+ countries.

The transaction includes Stemtech issuing 13 million preferred shares at $2.50, convertible to 50% of common stock. The deal completion is subject to due diligence, definitive agreements, and regulatory approvals.

Stemtech (OTCQB:STEK) has signed a merger agreement with Seacret Direct / VIÁGO through the issuance of 13 million preferred shares valued at $2.50 per share. The merger is expected to double Stemtech's revenue and create a vertically integrated company focused on health, longevity, and lifestyle solutions.

The transaction completion remains subject to conditions, including Seacret Direct / VIÁGO's audit, consents, and authorizations. The merged entity anticipates doubled revenue forecast for 2025 with planned cost synergies, aiming to deliver positive bottom-line results through optimization and existing growth trajectories.

Stemtech (OTCQB:STEK) and Viago have announced a strategic merger agreement. The all-stock transaction will see Charles S. Arnold continue as Chairman of the holding company, while Viago's Izhak Ben Shabat will become CEO. Stemtech, known for plant-based stem cell nutrition products with historical revenue of $600 million, will combine with Viago, a company focused on membership services, nutrition, and skincare. Both companies will maintain their individual channels while pursuing growth synergies. The merger completion is subject to board and shareholder approvals, definitive agreements, and Viago's financial audit.

Stemtech (STEK) announces a strategic realignment focusing on its fastest-growing markets: the United States, Mexico, Canada, Ecuador, and Taiwan. The company is expanding into the $303 billion pet health care market with the launch of StemPets™, leveraging its expertise in stem cell nutrition. Stemtech is also reinforcing its commitment to the anti-aging sector, led by its flagship product Stemrelease3™.

The company plans to integrate AI technology to enhance customer interactions and support. Stemtech is preparing to expand into Colombia as its next market. CEO Charles S. Arnold emphasizes the company's focus on allocating resources effectively to support distributors and customers. President & COO John W. Meyer highlights the benefits of AI integration for improving efficiency and customer experience.

Stemtech (STEK) has announced its uplisting to OTCQB, marking a significant milestone in its commitment to transparency and investor confidence. As a pioneer in stem cell nutrition, Stemtech is expanding its global footprint across the United States, Mexico, Ecuador, Canada, and Taiwan. The company offers innovative products in stem cell nutrition, skin care, oral care, and recently announced pet care technologies.

The global stem cells market is projected to grow from $14.92 billion in 2023 to $49.26 billion by 2034, with a CAGR of 11.47%. Stemtech's CEO, Charles S. Arnold, emphasizes the increasing awareness of stem cell benefits and the company's reasonably priced, life-maintenance system. With decades of research, Stemtech focuses on developing all-natural, plant-based stem cell products to enhance human and pet health, offering both health solutions and income-earning opportunities.

Stemtech (OTCQB:STEK) has launched StemPets™, a new product line for the $303 billion pet health care market. This natural stemceutical product, designed for dogs, cats, and other pets, aims to provide health benefits similar to Stemtech's human products. StemPets contains cashew nut-shell oil (Anacardic Acid) and a special stem cell nutrition formula to support organ repair, immune system, and joint health.

The product is non-GMO, free from artificial additives, and increases circulating stem cells in pets. Stemtech has secured an exclusive distribution agreement for StemPets. This expansion is expected to attract younger distributors, particularly Gen X individuals under 40. Stemtech has a history of delivering over $600 million worth of nutraceutical products with a return rate of less than 2%.

Stemtech (OTC Pink:STEK) CEO Charles S. Arnold addressed shareholders and Independent Business Partners regarding delays in SEC filings. The delays were attributed to an undisclosed asset acquisition and challenges with a new audit team unfamiliar with Stemtech's complex international business model. Despite being a $5 million revenue company, Stemtech's global presence required significant resources to meet auditors' requests.

The company's primary product, the RCM combination, has generated approximately $600 million in revenue with a low 2% return rate. Stemtech operates in the stem cell nutrition market, projected to reach $30 billion by 2030. The company is currently facing inventory challenges due to high product demand and is working on solutions to improve inventory levels.